NEWS | Innovation for Life

SINGAPORE, October 12, 2021 – Prestige Biopharma Limited, a Singapore-based biopharmaceutical with global presence, announced that PBP took part in a Korea-EU Global Vaccine Partnership Business Forum in Brussels, on October 08, 2021. Those attending included the South Korean Minister of Health and Welfare Kwon Deok-cheol, the South Korean Trade Minister Yeo Han-Koo, officials of the EU commission, Coalition for Epidemic Preparedness Innovations (CEPI), EU’s Bio Supply Management Alliance (BSMA) and the representatives of Korea-EU vaccine companies.

At the partnership forum, Vice Chairman of Prestige Biopharma Group Michael Jinwoo Kim gave a presentation on Prestige Biopharma’s business plan and vaccine production capacity to the Korea-EU government officials, and Prestige Biopharma discussed cooperation with the EU pharmaceuticals who have proprietary self-amplifying mRNA vaccine technology and cancer vaccine platform. There is potential to generate synergy between Prestige Biopharma vaccine business and these EU vaccine companies as Prestige Biopharma ultimately aims to develop its own vaccine products.

EU’s biomanufacturing equipment suppliers also attended the forum and showed interest in Korea’s vision for hosting an Asian vaccine production hub. Prestige Biopharma had a discussion with the manufacturing equipment supplier specialising in Drug Product (DP) bioprocessing equipment to secure a reliable supply chain for its vaccine business.

Dr. Lisa S. Park, CEO of Prestige Biopharma, commented, “We incorporated Innovative Discovery Center (IDC) in Busan, Korea this year and its global-scale R&D center will be completed next year. Prestige Biopharma will ultimately develop our own vaccine products and novel antibody therapeutics in the IDC Busan through innovative cooperation with global vaccine companies and organizations.”